is secreted in Sertoli cells and epididymal epithelial cells and plays important roles in the regulation of spermatogenesis and sperm maturation. To investigate whether endocrine disruptors affect spermatogenesis through an SGP-2-dependent mechanism, daily oral doses of testosterone (50, 200 and 1,000 µg/kg), flutamide (1, 5 and 25 mg/kg), ketoconazole (0.2, 1, 5 and 25 mg/kg), diethylhexylphthalate (10, 50 and 250 mg/kg), nonylphenol (10, 50, 100 and 250 mg/kg), octylphenol (10, 50 and 250 mg/kg), diethylstilbesterol (10, 20 and 40 µg/kg) or corn oil (control) were administered to 5 week-old, male Sprague-Dawley rats for 3 weeks. Following treatment with these endocrine disruptors, testicular expression of SGP-2 mRNA was analyzed using reverse transcription-polymerase chain reaction. Compared with the control, the lowest dose of testosterone (50 µg/kg/day) significantly increased expression of SGP-2 mRNA, whereas 200 and 1,000 µg/kg/day testosterone significantly decreased the expression (P<0.05). Flutamide, ketoconazole, diethylhexylphthalate, nonylphenol, octylphenol and diethylstilbesterol significantly decreased SGP-2 mRNA expression in testes at all doses studied, with the exception of 1 mg/kg/day flutamide (P<0.05). These results suggest that endocrine disruptors might decrease spermatogenesis in testes by decreasing expression of SGP-2 mRNA.
permatogenesis is a testosterone-dependent process [1] . In mammalian testes, spermatogenesis occurs in Sertoli cells [2] . Sertoli cells and epididymal epithelial principal cells have been shown to synthesize and secrete a number of glycoproteins that have been suggested to play important roles in the regulation of spermatogenesis and sperm maturation [3] . One of the major proteins secreted by both Sertoli cells and epididymal epithelial cells is sulfated glycoprotein-2 (SGP-2) [4] . SGP-2 is a heavily glycosylated protein composed of two monomers that arise from a proteolytically-cleaved, single chain polypeptide precursor [5] . In the reproductive tract, immunofluorescence has shown that SGP-2 is localized in the cytoplasm of Sertoli cells and in the heads and tails of spermatozoa [6] .
SGP-2 is a component of both bovine adrenal chromaffin granules and human neuroendocrine secretary granules and is induced in porcine smooth muscles cells during differentiation in vitro [7, 8] . High levels of SGP-2 have also been found in the brain after biological insults such as Alzheimer's disease and hippocampal lesions [9, 10] . The SGP-2 protein has been considered to be a possible participant in a number of biological activities, including inhibition of the C' cascade, protection of cells from injurious environments, mediation of apoptosis, lipid metabolism and transport, remodeling of cell membranes, cell-cell interactions and differentiation and maturation of germ cells [11] [12] [13] .
Many studies have shown that exposure to endocrine disruptors during prenatal or early postnatal life can disturb development of the endocrine system and organs that respond to endocrine signals [14] . Anti-androgenic endocrine disruptors inhibit spermatogenesis and exhibit other antigonadotropic effects. Flutamide (FM) is an antiandrogen that has been shown to have a relatively small and transient influence on spermatogenesis. FM inhibits the initial step of spermatogenesis, resulting in reduced sperm counts in rats [15] . Ketoconazole (KC) has less of an effect on spermatogenesis, but more readily decreases epididymal sperm number and motility, increases the proportion of abnormal sperm [16] and induces reversible immobilization of mature spermatozoa in the post-testicular sex organs [17] . Diethylhexylphalate (DEHP) has been shown to produce seminiferous tubule degenerat i o n , r e s u l t i n g i n t e s t i c u l a r a t r o p h y [ 1 8 ] . Octylphenol (OP) has been shown to profoundly suppress testicular function in adult male rats, as evidenced by low levels of circulating testosterone, suppression of spermatogenesis [19] , reduced sperm counts and testicular atrophy [20] following treatment with OP. Nonylphenol (NP) has been shown to act directly on male reproductive tissues [21] to decrease testicular size [22] . Diethylstilbesterol (DES) has been shown to inhibit testicular formation in rats, resulting in abnormal semen production and infertility [23, 24] .
The Sertoli cell is the only cell type shown to have a significant level of SGP-2 mRNA in the testes by in situ hybridization [25] . Plotton et al. (2005) reported that the amount of SGP-2 (clusterin) mRNA is a good marker of the amount of mRNA of Sertoli cell origin in the testes of post pubertal rats [26] . In the present study, we examined the effects of various endocrine disruptors on spermatogenesis using SGP-2 mRNA expression as a biomarker for spermatogenesis in the Sertoli cells of rat testes.
Materials and Methods

Animals and pharmacological treatments
Four-week-old Sprague-Dawley rats (Samtaco Inc., Gyeonggido, Korea) were housed for 1 week in polycarbonate cages with a temperature of 21 ± 2 C, a relative humidity of 50 ± 10% and a 12-h light/ dark cycle. The animals were fed standard rat pellets (Purina Inc., Gyeonggido, Korea), and water ad libitum. All experiments were approved and carried out according to the "Guide for Care and Use of Animals" (Chungbuk National University Animal Care Committee according to NIH #86-23).
The endocrine disruptors testosterone propi- 
Total RNA extraction and reverse transcriptionpolymerase chain reaction (RT-PCR)
Total RNA was extracted from testes using TRIzol Reagent (Life Technologies, Gaithersburg, MD, USA) according to the manufacturer's instructions. The RNA pellet obtained in the final step was dissolved in 50 µl of sterile diethylpyrocarbonate (DEPC) treated water, and its concentration was determined using a UV spectrophotometer at 260 nm. The RNA was kept in DEPC-treated water at -70 C until use. Reverse transcription of mRNA and amplification of cDNA were performed using a Peltier Thermal Cycler (MJ Research, Waltham, MA, USA).
A cDNA Synthesis Kit (Roche Diagnostics, Mannheim, Germany) was used to generate cDNA from 1.0 µg total RNA according to the manufacturer's instructions. The primer sets used for amplification of SGP-2 (GenBank accession number: X13231) were 5'-ACAGCAGGAGTTCTCTGACA-3' (forward) and 5'-TAGCATCTAGGACTTGGCTC-3' (reverse), and those used for amplification of GAPDH as an internal control [27] were 5'-AAC-CGGATTTGGTCGTATTGG-3' (forward) and 5'-A G C C T T C T C C A A T G G T G G T G A A G A C -3 ' (reverse). The amplification conditions for each cDNA were 2 min of initial denaturation at 94 C; 35 cycles of 94 C for 20 sec, 58 C for 10 sec and 72 C for 30 sec; and 5 min of final elongation at 72 C. The PCR products were run on 2% agarose gel in Trisborate-EDTA buffer. The expected PCR product sizes for SGP-2 and GAPDH were 437 and 302 bp, respectively. The results were analyzed with the AlphaEase V5.5 analysis software (Alpha Innotech, San Ledro, CA, USA). Specific primers to mouse GAPDH were used as an internal standard.
Statistical analysis
The data were analyzed by analysis of variance (ANOVA) followed by Duncan's test for post-hoc analysis (SPSS, Cary, NC, USA). Statistical significance was set at P<0.05. All data are presented as means ± SD.
Results
Daily treatment with endocrine disruptors resulted in a general decrease in SGP-2 expression, except for treatment with testosterone. A dose of 50 µg/kg/day testosterone increased the expression of SGP-2 mRNA. However, larger doses of testosterone (200 and 1,000 µg/kg/day) significantly decreased SGP-2 mRNA expression by 80 and 50%, respectively (Fig. 1) . FM decreased the SGP-2 mRNA level to 35-40% of the control level (Fig. 2) , whereas KC dose-dependently decreased SGP-2 mRNA expression to 70-15% of the control level (Fig. 3) . Treatment with DEHP significantly decreased SGP-2 mRNA expression to 10-40% of the control level (Fig. 4) . SGP-2 mRNA expression was significantly decreased (50-85%) after treatment with OP. Specifically, 50 mg/kg of OP decreased SGP-2 mRNA expression to 15% of the control level (P<0.05; Fig. 5 ). In the NP-treated rats, SGP-2 mRNA expression was significantly (P<0.05) reduced to 65-90% of the control level (Fig. 6) . SGP-2 mRNA expression in the rats treated with DES was 15-38% lower than that of the control animals (Fig. 7) . 
Discussion
The aim of this study was to examine the changes of SGP-2 mRNA expression in rat testes after treatment with various endocrine disruptors, including testosterone, FM, KC, DEHP, NP, OP and DES. The results presented here demonstrate that endocrine disruptors have different effects on SGP-2 mRNA expression in rat testes.
SGP-2 mRNA is a well-established biomarker of steroidogenesis in Sertoli cells. Testosterone, the principal circulating androgen in the adult male, is essential for maintenance of spermatogenesis and expression of secondary sex characteristics. Thus, production of testosterone is highly regulated by a negative feedback system in the testes [28] . This study showed that treatment with high doses of testosterone (200 and 1,000 µg/kg/day) decreased SGP-2 mRNA expression, while treatment with a lower dose of testosterone (50 µg/kg/ day) increased SGP-2 mRNA expression compared with the control. This finding is consistent with the expression of SGP-2 being governed by a negative f e e d b a c k m e c h a n i s m t h a t i s r e g u l a t e d b y testosterone. FM is an antiandrogenic compound and a nonsteroidal androgen receptor (AR) antagonist that interferes with endogenous androgen binding to ARs in target organs [29] . FM has been shown to cause degeneration of the seminiferous epithelium and hyperplasia of interstitial cells (Leydig cells) in the rat testes [30] . In the present study, SGP-2 mRNA expression was significantly decreased in all FM-treated groups compared with the control. These results suggest that spermatogenesis is inhibi t e d b y F M -i n d u c e d d e g e n e r a t i o n o f t h e seminiferous epithelium of the testes.
KC-treated animals showed a dose-dependent decrease in SGP-2 mRNA expression compared with the control. KC inhibits biosynthesis of testosterone by blocking 17,20-desmolase activity in the testes [31] . Thus, the KC-induced decrease in SGP-2 mRNA expression observed in the present study might be mediated by decreased biosynthesis of testosterone via inhibition of 17,20-desmolase enzyme activity.
DEHP treatment decreased SGP-2 mRNA expression in the testes compared with the control treatment. This finding is consistent with previous reports that perinatal exposure of male rats to DEHP produces adverse effects in androgenresponsive tissues [32] . Specifically, 2,000 mg/kg/ day DEHP has been previously shown to cause testicular atrophy [24] , damage to the seminiferous epithelium [33] and reduced epididymal sperm density and motility [34] in rats.
OP is an alkylphenolic compound that is formed from some nonionic surfactants widely used in industrial detergents, such as plastic and petrol additives and dispensers for insecticides [35] . OP has been shown to decrease the expression of steroidogenesis factor-1 (SF-1) mRNA in fetal testes [36] , to suppress gonadotropin secretion [37] , and to have toxic effects on seminiferous cells in vitro [35] . In the present study, treatment with OP (10, 50, 100 and 250 mg/kg/day) resulted in a significant decrease in SGP-2 mRNA expression.
NP is an estrogenic compound that can be generated from alkylphenol ethoxylates widely used in the production of plastics, textiles, agricultural chemicals, household chemicals and cosmetics [38] . Several studies have reported that animals parentally exposed to NP exhibit atrophied seminiferous tubules and decreased spermatogenesis [39] . In the present study, NP significantly decreased SGP-2 mRNA expression at all doses studied (10, 50, 100 and 250 mg/kg/day), suggesting that inhibition of SGP-2 mRNA expression by NP and OP might be due to functional defects in the testes, such as atrophied seminiferous and spermatogenic cells.
DES is an antiandrogenic compound that has been used therapeutically to prevent miscarriage and other pregnancy complications. It has been reported to reduce the activity of SF-1 in 17.5-dayold fetuses [40] . Other studies have reported that exposure of rats to DES results in a significant reduction in epididymal sperm count, atrophy of sperm motion, decrease in Sertoli cell number and increase in spermatogenic cell apoptosis [41] . In the present study, DES treatment inhibited SGP-2 mRNA expression in the testes, suggesting that decreased SGP-2 expression might inhibit spermatogenesis and reduce testosterone production in the testes. In conclusion, this study showed that several endocrine disruptors changed the expression pattern of SGP-2 mRNA in the testes as determined by RT-PCR. These results suggest that the effects of endocrine disruptors on spermatogenesis in the testes might be mediated by an abnormal change in SGP-2 mRNA expression.
